Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 76 to 79 of 79 results for cyclophosphamide

  1. Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment (TA1139)

    Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment in adults.

    Technology appraisal guidance
    Published
    11 March 2026
    View recommendations

    Sections for TA1139

  2. Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA954)

    Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.

    Technology appraisal guidance
    Published
    6 March 2024
    View recommendations

    Sections for TA954

  3. NICE recommends new chemotherapy-free treatment option for people with untreated chronic lymphocytic leukaemia

    More than 1,000 people each year will benefit from NICE's recommendation.

    News
    Last updated
    15 January 2024

  4. Chemotherapy-free treatment option to be offered to patients with England's most common leukaemia

    Acalabrutinib, taken as a twice daily tablet, is recommended as an option for adults with untreated chronic lymphocytic leukaemia.

    News
    Last updated
    19 January 2024